Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Kin-2787 Free Base
2. 2vpx8hl8ab
3. Exarafenib [inn]
4. Unii-2vpx8hl8ab
5. Schembl23275448
6. Gtpl12095
7. Bdbm514652
8. Us11098031, Example 14
9. Example 14 [wo2021081375a1]
10. Hy-147268
11. Cs-0542473
12. (3s)-n-(3-(2-(((2r)-1-hydroxypropan-2-yl)amino)-6- (morpholin-4-yl)pyridin-4-yl)-4-methylphenyl)-3-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide
13. (3s)-n-[3-[2-[[(2r)-1-hydroxypropan-2-yl]amino]-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
14. (s)-n-(3-(2-(((r)-1-hydroxypropan-2- Yl)amino)-6-morpholinopyridin-4-yl)-4- Methylphenyl)-3-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide
15. 1-pyrrolidinecarboxamide, N-(3-(2-(((1r)-2-hydroxy-1-methylethyl)amino)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)-, (3s)-
16. 2639957-39-2
| Molecular Weight | 521.6 g/mol |
|---|---|
| Molecular Formula | C26H34F3N5O3 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 521.26137445 g/mol |
| Monoisotopic Mass | 521.26137445 g/mol |
| Topological Polar Surface Area | 90 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 739 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Exarafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Exarafenib, including repackagers and relabelers. The FDA regulates Exarafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Exarafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Exarafenib supplier is an individual or a company that provides Exarafenib active pharmaceutical ingredient (API) or Exarafenib finished formulations upon request. The Exarafenib suppliers may include Exarafenib API manufacturers, exporters, distributors and traders.
Exarafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Exarafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Exarafenib GMP manufacturer or Exarafenib GMP API supplier for your needs.
A Exarafenib CoA (Certificate of Analysis) is a formal document that attests to Exarafenib's compliance with Exarafenib specifications and serves as a tool for batch-level quality control.
Exarafenib CoA mostly includes findings from lab analyses of a specific batch. For each Exarafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Exarafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Exarafenib EP), Exarafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Exarafenib USP).
LOOKING FOR A SUPPLIER?
